Gilead Sciences Inc. and Glympse Bio have announced that the companies have entered into a strategic collaboration in nonalcoholic steatohepatitis (NASH) clinical development.

Glympse Bio’s proprietary synthetic biomarkers – bioengineered to identify stage and progression of disease as well as early detection of treatment response – will be used to determine clinical trial participants’ stage of disease at initial screening and to determine responses to study treatment in Gilead’s NASH clinical program.

“We are excited about the opportunity to partner with Glympse Bio to help inform our NASH development program,” saidMani Subramanian, Senior Vice President, Liver Diseases,Gilead Sciences. “By utilizing this innovative technology, we hope to better characterize this complex disease and improve our understanding of how our compounds impact disease progression.”

Glympse Bio’s technology, Glympse Inside, combines synthetic biomarkers with machine learning approaches to identify the stage and monitor progression of important, complex diseases such as cancer, fibrosis, inflammation, and infections, in real time.

Glympse Bio’s synthetic biomarkers will be used to determine clinical trial participants’ stage of disease to determine responses to treatment in Gilead’s NASH clinical program.